[Curative machanism of Shenle capsule on 5/6 nephrectomy rats].
OBJECTIVE
To explore curative machanism of Shenle capsule on the 5/6 nephrectomy rats.


METHODS
Fibrin plate method was applied to examine activity of urinary plasminogen activator(PA). Semi-quantitative analysis was used to observe stained intensity and area of tissue-type plasminogen activator, urokinas-type plasminogen activator/ plasminogen activator inhibitor(tPA, uPA/PAI-1)in remnant renal tissue. Northern blot was employed to analyze the expression of transforming growth factor (TGF-beta) mRNA.


RESULTS
In model control group, the urinary PA activity and protein expression of tPA, uPA were down-regulated, but protein expression of PAI-1, TGF-beta mRNA was up-regulated in remnant renal tissue. In each treated group, the urinary PA activity and protein expression of tPA/uPA were enhanced,but the protein expression of PAI-1, TGF-beta mRNA decreased simultaneously.


CONCLUSIONS
Shenle capsule can delay glomerulosclersis and tubulointerstitial fibrotic lesions of remnant kidney by improving the activity of urinary PA and modulating the expression of tPA, uPA/PAI-1 and TGF-beta mRNA.
Wei
Ri-Bao
RB
[Division of Nephrology, Kidney Center & Key Lab of Chinese PLA, General Hospital of Chinese PLA, Beijing 100853, China.
Zhang
Wu-Xing
WX
Chen
Xiang-Mei
XM
D000818:Animals; D002214:Capsules; D029745:Codonopsis / Q000737:chemistry; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology*; D005260:Female; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism*; D007865:Leeches / Q000737:chemistry; D008297:Male; D008419:Materia Medica / Q000302:isolation & purification / Q000494:pharmacology*; D009392:Nephrectomy; D015849:Plasminogen Inactivators / Q000378:metabolism; D020072:Polyporales / Q000737:chemistry; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D002214:Capsules; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D008419:Materia Medica; D015849:Plasminogen Inactivators; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator